News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.
|Title||5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.|
|Publication Type||Journal Article|
|Year of Publication||2011|
|Authors||Bolaños-Meade J, Smith DB, Gore SD, McDevitt MA, Luznik L, Fuchs EJ, Jones RJ|
|Journal||Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation|
|Date Published||2011 May|
Relapse after allogeneic blood or marrow transplantation carries a very poor prognosis. Current strategies for management that include donor lymphocyte infusions (DLIs) and salvage chemotherapies are usually toxic and ineffective. Here we report the outcome of 10 patients with myeloid malignancies that received 5-azacytidine after a failed allogeneic bone marrow transplant. Of the 10 patients, 6 achieved a complete remission, 1 had stable disease, and 3 progressed after a median of 6 cycles administered. Only 1 patient has died (of disease progression), and no flares of graft-versus-host disease (GVHD) were observed with 5-azacytidine. As of latest follow-up, the median overall survival (OS) for the group was 422.5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted.
|Alternate Journal||Biol. Blood Marrow Transplant.|